Chinese drug discovery startup Meta Pharmaceuticals has raised a combined $15 million from its seed and Series pre-A rounds of financing to develop innovative therapeutics for patients suffering from autoimmune diseases.
The startup’s two incubators — Forcefield Ventures and XtalPi Inc, a China-US artificial intelligence (AI) drug discovery company — invested in the rounds alongside IMO Ventures and Tiantu Capital, according to a statement.